Navigation Links
New Phase 3 Study Published in The Lancet Evaluates Efficacy and,Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination,Therapy in Treatment-Experienced Adults With HIV

BRIDGEWATER, N.J., July 05, 2007 /PRNewswire/ -- Results from the primary analysis of a randomized, controlled, open-label, Phase 3 study showed that 77 percent of treatment-experienced HIV-1 infected adults taking PREZISTA(TM) (darunavir) 600 mg tablets with 100 mg ritonavir (PREZISTA/r) twice daily, plus an optimized background regimen (OBR) of antiretroviral (ARV) agents, reached a plasma viral load of <400 copies/mL at week 48, compared to 68 percent of patients taking Kaletra(R)1 (lopinavir/ritonavir) 400 mg/100 mg twice daily, plus OBR in a per-protocol analysis. The mean difference in response was nine percent and was statistically significant (95 percent confidence interval 2-16).

The 48-week efficacy and safety results, published in the July 7, 2007 issue of The Lancet, will also be presented at the 4th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention (IAS 2007) in Sydney, Australia on July 24, 2007.

The Phase 3 study, known as TITAN, (TMC114/r In Treatment-experienced pAtients Naive to lopinavir/ritonavir), compared the efficacy and safety of PREZISTA/r with the protease inhibitor (PI) lopinavir/r in treatment- experienced adult patients who were lopinavir/r-naive. The primary endpoint of this study was non-inferiority (95 percent CI lower limit for the difference in treatment response -12 percent or greater) for HIV RNA of less than 400 copies per mL in plasma at week 48 (per-protocol analysis).

"This is exciting new information that adds to the body of knowledge on PREZISTA in a much broader group of treatment-experienced patients," said Daniel Berger, MD, medical director of NorthStar Healthcare and clinical assistant professor of medicine at the University of Illinois, Chicago.

The 48-week primary analysis from the TITAN study provides additional information regarding efficacy and safety of PREZISTA/r in combination with other ARV agen
'"/>




Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
3. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
4. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
6. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
7. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
8. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
9. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
10. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
11. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
Post Your Comments:
(Date:5/22/2015)... BOTHELL, Wash. , May 22, 2015  BioLife Solutions, ... marketer of proprietary clinical grade hypothermic storage and ... products for cells and tissues ("BioLife" or the "Company"), ... 2015 Marcum MicroCap Conference. The Company is ... on Wednesday, May 27, 2015 at the Grand Hyatt Hotel ...
(Date:5/22/2015)... 22, 2015 The Assistance Fund announces the ... provides financial assistance for copay to individuals diagnosed with ... the addition of the Melanoma Copay Assistance Program to ... , executive director. "With each additional program we are ... world where no one is denied access to medications ...
(Date:5/22/2015)... Electrophysiologist Kevin Makati, M.D. with St. ... Boston, MA to speak about ... Society conference. These scientific sessions drew more than ... people and technology that propel their specialty forward. ... invasive cardiac operation that combines the expertise of ...
Breaking Medicine Technology:BioLife Solutions To Present At The 2015 Marcum MicroCap Conference In New York City 2The Assistance Fund Adds Melanoma Assistance Program 2St. Joseph's Hospital Heart Institute Physician Presents at Heart Rhythm Society 2St. Joseph's Hospital Heart Institute Physician Presents at Heart Rhythm Society 3
... of New Anti-TNF Therapy in Three Rheumatic Diseases with ... KENILWORTH, N.J., June 26 Centocor Ortho Biotech Inc. ... today that the Committee for Medicinal Products for Human ... a positive opinion recommending the approval of SIMPONI(TM) (golimumab) ...
... Once-Daily Treatment of Pseudomonas Lung Infections , , ... Therapeutics Inc., the nonprofit affiliate of the Cystic Fibrosis ... Inc., for the continued development of ARIKACE(TM) (liposomal amikacin ... Pseudomonas lung infections in cystic fibrosis (CF) and ...
Cached Medicine Technology:SIMPONI(TM) (golimumab) Receives Positive Opinion From CHMP for Once-Monthly Subcutaneous Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis 2SIMPONI(TM) (golimumab) Receives Positive Opinion From CHMP for Once-Monthly Subcutaneous Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis 3SIMPONI(TM) (golimumab) Receives Positive Opinion From CHMP for Once-Monthly Subcutaneous Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis 4SIMPONI(TM) (golimumab) Receives Positive Opinion From CHMP for Once-Monthly Subcutaneous Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis 5SIMPONI(TM) (golimumab) Receives Positive Opinion From CHMP for Once-Monthly Subcutaneous Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis 6SIMPONI(TM) (golimumab) Receives Positive Opinion From CHMP for Once-Monthly Subcutaneous Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis 7SIMPONI(TM) (golimumab) Receives Positive Opinion From CHMP for Once-Monthly Subcutaneous Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis 8SIMPONI(TM) (golimumab) Receives Positive Opinion From CHMP for Once-Monthly Subcutaneous Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis 9SIMPONI(TM) (golimumab) Receives Positive Opinion From CHMP for Once-Monthly Subcutaneous Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis 10Transave Receives $2.2 Million Cystic Fibrosis Foundation Award for Development of ARIKACE(TM) 2Transave Receives $2.2 Million Cystic Fibrosis Foundation Award for Development of ARIKACE(TM) 3Transave Receives $2.2 Million Cystic Fibrosis Foundation Award for Development of ARIKACE(TM) 4
(Date:5/22/2015)... Following yesterday’s announcement that Ascenta Health ... health brand Nature’s Way, Marc St-Onge has affirmed his ... Skin is an integral part of the agreement with ... to further develop Ascenta Skin into a leading player ... a breakthrough, anti-aging skincare supplement featuring 6 active ingredients ...
(Date:5/22/2015)... 2015 Omar Ahmad Barrada, a junior ... in the 2015 Congress of Future Medical Leaders in ... gathering of “America’s highest achieving high school students.” , ... set new goals and learn better study habits,” said ... during which we can ask the surgeons questions.” , ...
(Date:5/22/2015)... May 22, 2015 Combination therapy, ... option for chronic obstructive pulmonary disorder (COPD) as ... and AstraZeneca plc as well as Germany’s Boehringer ... and position. But will market payers, clinicians and ... well-entrenched products to completely new ones? , In ...
(Date:5/22/2015)... 22, 2015 Hands On HealthCare Massage ... 2015, the Annual One Day Sale on Massage ... On HCMT offers drastically reduced certificates one day a year. ... enough sessions, through what used to be the slowest time ... the community as well. This once a year occurrence has ...
(Date:5/22/2015)... 2015 “It’s like learning an ... CHHRP-QT, Vice President of Clinical Operations/Education and Training ... that impacts how care is coded and reimbursed.” ... term care reimbursement, operations and compliance consulting, as ... management, launches a new series of day-long seminars ...
Breaking Medicine News(10 mins):Health News:Ascenta Skin President Announces Plans to Grow Brand 2Health News:Milton Hershey School Student Chosen for Congress of Future Medical Leaders 2Health News:Chronic Obstructive Pulmonary Disorder Therapeutics Market Discussed in In-demand FirstWord Report Published at MarketPublishers.com 2Health News:Hands On HealthCare Massage Therapy & Wellness Day Spa Announces Their Eighth Annual One Day Sale on Gift Certificates Will Take Place on June 17, 2015 2Health News:Hands On HealthCare Massage Therapy & Wellness Day Spa Announces Their Eighth Annual One Day Sale on Gift Certificates Will Take Place on June 17, 2015 3Health News:Harmony Healthcare International Takes the Lead in Launching ICD-10 Coding Transition in Post-Acute Care 2Health News:Harmony Healthcare International Takes the Lead in Launching ICD-10 Coding Transition in Post-Acute Care 3
... more attention to choosing the doctor, not the device ... as a safe and long-lasting way to alleviate hip-related ... fails, the problem more often lies with surgical error ... , , Dislocation of the implant was the most common ...
... gene is a key to understanding, and perhaps killing, ... only to reawaken years later, researchers at The University ... the December Journal of Clinical Investigation . , ... ARHI acts as a switch for autophagy, or self-cannibalization, ...
... that Lewy bodies, clumps of aggregated proteins inside ... Parkinson,s disease and other neurodegenerative diseases. , The ... protein recycling and waste disposal, leading to the ... cells? , One possible answer: by breaking a ...
... supplementation was found to be effective in relieving pain ... chronic pancreatitis (CP), reports a new study in ... the pancreas in which patients experience abdominal pain (in ... Pain is the major problem in 90 percent of ...
... from presence of salicylic acid in study participants , , ... key component that gives aspirin its anti-inflammatory and pain-relieving ... own, a new study suggests. , Salicylic acid (SA) ... who had not taken aspirin recently -- especially vegetarians. ...
... organ improved odds, study shows , , WEDNESDAY, Dec. 31 ... donated kidney raised the chances of a successful transplant ... European researchers report. , The study, published in the ... of Medicine , got generally favorable reviews from American ...
Cached Medicine News:Health News:Surgeons Often Are Blamed When Hip Replacements Fail 2Health News:Surgeons Often Are Blamed When Hip Replacements Fail 3Health News:Dormant cancer cells rely on cellular self-cannibalization to survive 2Health News:Toxicity mechanism identified for Parkinson's disease 2Health News:Antioxidants offer pain relief in patients with chronic pancreatitis 2Health News:A Better Method of Kidney Storage 2Health News:A Better Method of Kidney Storage 3
... superb field flatness, high UV transmission ... extra long working distances, these objectives ... with inverted microscopes. Because of their ... ELWD DM,objectives can be used universally ...
Inquire...
... Axiovert 40 inverted microscope ... have ever expected from a microscope in this ... quality, and functionality. Axiovert 40 has been designed ... as possible thus increasing the efficiency of ...
... is an advanced inverted microscope ... exclusive CFI60 optical system yields ... aperatures and longer working distances. ... to take full advantage of ...
Medicine Products: